524636
Oxygenta Pharma financials
- Market cap
- ₹207 Cr
- Sector
- Healthcare
What Oxygenta Pharma does
Oxygenta Pharmaceutical Limited is a company in the pharmaceutical industry, commercially operational since November 1990, with its registered office at Aroor Village, Sadasivapet Mandal, Medak district, Telangana, and a corporate office in Hyderabad. It functions within the Virupaksha Organics Limited group, which holds a majority stake and is its promoter and holding company; the company's sales and purchases are transacted with this holding company. Its executive leadership includes directors with a long background in the bulk-drug and active pharmaceutical ingredient (API) side of the pharmaceutical industry.
Quarterly results
Q1 FY27: revenue up 144.5%, net profit up 65.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14 | 33 | 49 | 15 | 14 +2% | 34 +2% | 50 +0% | 37 +145% |
| EBITDA | -2 | -4 | -2 | -7 | -5 −111% | -4 +6% | 0 +107% | 1 +108% |
| Net profit | -3 | -4 | -2 | -6 | -5 −73% | -5 −23% | -2 +21% | -2 +66% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −21.6% 1Y
1Y: ₹71.26 on 10 Sept 2025 → ₹55.88. High ₹71.99 (12 Sept 2025), low ₹44.61 (11 Jun 2026).
Financials, as filed
Revenue grew 53.9% a year over 3 years, FY23 to FY26. Operating margin widened to -13.6%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹31 Cr | ₹40 Cr | ₹109 Cr | ₹113 Cr |
| Operating profit | ₹-7 Cr | ₹-10 Cr | ₹-10 Cr | ₹-15 Cr |
| Operating margin | -23.0% | -24.5% | -9.1% | -13.6% |
| Interest | ₹1 Cr | ₹2 Cr | ₹4 Cr | ₹5 Cr |
| Depreciation | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr |
| Net profit | ₹-12 Cr | ₹-3 Cr | ₹-10 Cr | ₹-18 Cr |
| Net margin | -37.3% | -8.8% | -9.4% | -15.6% |
| Cash from operations | ₹-2 Cr | ₹-13 Cr | ₹3 Cr | ₹-28 Cr |
| Free cash flow | ₹-11 Cr | ₹-17 Cr | ₹-8 Cr | ₹-41 Cr |
| ROCE | -47.0% | -42.0% | -33.0% | -34.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹10 Cr | ₹14 Cr | ₹14 Cr | ₹33 Cr | ₹37 Cr | ₹37 Cr |
| Reserves | ₹-48 Cr | ₹-49 Cr | ₹-60 Cr | ₹-54 Cr | ₹-74 Cr | ₹-80 Cr |
| Borrowings | ₹48 Cr | ₹52 Cr | ₹68 Cr | ₹57 Cr | ₹73 Cr | ₹110 Cr |
| Other liabilities | ₹24 Cr | ₹14 Cr | ₹32 Cr | ₹26 Cr | ₹81 Cr | ₹53 Cr |
| Total liabilities | ₹34 Cr | ₹31 Cr | ₹54 Cr | ₹63 Cr | ₹117 Cr | ₹120 Cr |
| Fixed assets | ₹16 Cr | ₹20 Cr | ₹28 Cr | ₹29 Cr | ₹41 Cr | ₹48 Cr |
| Capital work in progress | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹17 Cr | ₹11 Cr | ₹26 Cr | ₹34 Cr | ₹75 Cr | ₹72 Cr |
| Total assets | ₹34 Cr | ₹31 Cr | ₹54 Cr | ₹63 Cr | ₹117 Cr | ₹120 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, promoters trimmed −1.42 pp while the public added +1.41 pp. The shareholder count grew 1% to 10,196.
- Promoters
- 56.5%
- DIIs
- 0.0%
- Public
- 43.4%
Since Jun 2025
- Promoters −1.42 pp
- Public +1.41 pp
- DIIs 0.00 pp
How it drifted, 12 quarters
Over this window the public fell from 70.2% to 43.4% — −26.8 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 29.7%, DIIs 0.0%, Public 70.2%.Dec '23: Promoters 29.7%, DIIs 0.0%, Public 70.2%.Mar '24: Promoters 29.7%, DIIs 0.0%, Public 70.2%.Jun '24: Promoters 33.7%, DIIs 0.0%, Public 66.3%.Sep '24: Promoters 53.3%, DIIs 0.0%, Public 46.7%.Dec '24: Promoters 51.1%, DIIs 0.0%, Public 48.8%.Mar '25: Promoters 51.1%, DIIs 0.0%, Public 48.8%.Jun '25: Promoters 58.0%, DIIs 0.0%, Public 42.0%.Sep '25: Promoters 58.0%, DIIs 0.0%, Public 42.0%.Dec '25: Promoters 55.9%, DIIs 0.0%, Public 44.0%.Mar '26: Promoters 56.5%, DIIs 0.0%, Public 43.4%.Jun '26: Promoters 56.5%, DIIs 0.0%, Public 43.4%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Oxygenta Pharma above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Virupaksha Organics Limited | 56.50% | unchanged |
| Sravani Reddy Gantla | 6.78% | unchanged |
| Subba Reddy Bhimavarapu | 4.14% | unchanged |
| Sunil V. Chawda | 2.97% | unchanged |
| Kumuda Katasani | 2.27% | unchanged |
| Aakanksha M Chawda | 1.54% | unchanged |
| Manoj S. Chawda | 1.54% | unchanged |
| Snigdha Vankineni | 1.47% | unchanged |
| Devarapally Venkateswara Reddy | 1.31% | unchanged |
| Satyanarayana Reddy Bandi | 1.29% | unchanged |
| B Subba Reddy | 1.26% | unchanged |
| Chandra Mouliswar Reddy Gangavaram | 0.03% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Oxygenta Pharma
Guides on how to read this kind of business and the numbers that matter.